Frazer Morgan
Chief Development Officer / Co-founder

Frazer Morgan has served as Chief Development Officer of Kinaset Therapeutics since 2020. He has over 27 years of experience in the development of inhaled therapies. Prior to co-founding Kinaset, Frazer held various development roles over an eight year period at 3M Healthcare before joining Vectura in 2003. Whist at Vectura, Frazer was involved in transforming the company from being privately held and VC-backed to a publicly traded company. Additionally, he was responsible for the leadership of multiple inhaled product development programs including AD237 which was out licensed to Novartis and became the successful COPD therapies Seebri™, Ultibro™ and Enerzair™. In addition to being a member of the Vectura Business Leadership Team, Frazer assumed a number of senior roles in product and commercial development and latterly was VP of Programme Development with overall responsibility for development of existing assets and the introduction of new assets to the branded inhaled product pipeline.